These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 2882993)

  • 1. Esmolol: a novel cardioselective, titratable, intravenous beta-blocker with ultrashort half-life.
    Covinsky JO
    Drug Intell Clin Pharm; 1987 Apr; 21(4):316-21. PubMed ID: 2882993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.
    Angaran DM; Schultz NJ; Tschida VH
    Clin Pharm; 1986 Apr; 5(4):288-303. PubMed ID: 2871961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia.
    Sung RJ; Blanski L; Kirshenbaum J; MacCosbe P; Turlapaty P; Laddu AR
    J Clin Pharmacol; 1986 Mar; 26(S1):A15-A26. PubMed ID: 2870082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker.
    Gray RJ
    Chest; 1988 Feb; 93(2):398-403. PubMed ID: 2892647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings.
    Turlapaty P; Laddu A; Murthy VS; Singh B; Lee R
    Am Heart J; 1987 Oct; 114(4 Pt 1):866-85. PubMed ID: 2889341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias.
    Gray RJ; Bateman TM; Czer LS; Conklin CM; Matloff JM
    J Am Coll Cardiol; 1985 Jun; 5(6):1451-6. PubMed ID: 2860148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
    Barbier GH; Shettigar UR; Appunn DO
    Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esmolol: a short-acting titratable beta-blocker in acute myocardial ischemia.
    Viray R; Turlapaty P; Laddu A
    Int J Clin Pharmacol Ther Toxicol; 1988 Mar; 26(3):153-61. PubMed ID: 2900818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Esmolol in anesthesiology: pharmacology and indications].
    Fita G; Gomar C; Rovira I
    Rev Esp Anestesiol Reanim; 1999 Nov; 46(9):404-14. PubMed ID: 10613078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Esmolol as a bolus for prevention of sympathetic adrenergic reactions following induction of anesthesia].
    Schäffer J; Karg C; Piepenbrock S
    Anaesthesist; 1994 Nov; 43(11):723-9. PubMed ID: 7840400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of esmolol during anesthesia to treat tachycardia and hypertension.
    Gold MI; Sacks DJ; Grosnoff DB; Herrington C; Skillman CA
    Anesth Analg; 1989 Feb; 68(2):101-4. PubMed ID: 2563314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group.
    Anderson S; Blanski L; Byrd RC; Das G; Engler R; Laddu A; Lee R; Rajfer S; Schroeder J; Steck JD
    Am Heart J; 1986 Jan; 111(1):42-8. PubMed ID: 2868645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of an ultrashort-acting beta-receptor blocker (esmolol) in patients with acute myocardial ischemia and relative contraindications to beta-blockade therapy.
    Kirshenbaum JM; Kloner RF; McGowan N; Antman EM
    J Am Coll Cardiol; 1988 Sep; 12(3):773-80. PubMed ID: 2900259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, in children.
    Cuneo BF; Zales VR; Blahunka PC; Benson DW
    Pediatr Cardiol; 1994; 15(6):296-301. PubMed ID: 7838803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and antiarrhythmic effects of esmolol in children.
    Trippel DL; Wiest DB; Gillette PC
    J Pediatr; 1991 Jul; 119(1 Pt 1):142-7. PubMed ID: 1676729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled beta-receptor blockade with esmolol and flestolol.
    Murthy VS; Frishman WH
    Pharmacotherapy; 1988; 8(3):168-82. PubMed ID: 2902602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Esmolol--beta-adrenergic blocking agent with ultrashort action].
    Marenović T; Stojiljković MP; Marković M
    Srp Arh Celok Lek; 1992 Jun; 120 Suppl 4():65-70. PubMed ID: 18193815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics and therapeutic efficacy of esmolol.
    Wiest DB; Haney JS
    Clin Pharmacokinet; 2012 Jun; 51(6):347-56. PubMed ID: 22515557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.
    Wiest D
    Clin Pharmacokinet; 1995 Mar; 28(3):190-202. PubMed ID: 7758250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupont critical care lecture: role of ultrashort-acting beta-blockers in the perioperative period.
    Kaplan JA
    J Cardiothorac Anesth; 1988 Oct; 2(5):683-91. PubMed ID: 17171962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.